Mark A. Velleca
CIK: 0001706847
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BDTX
Black Diamond Therapeutics, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
About Velleca Mark A.
Velleca Mark A. (SEC CIK 0001706847) files insider reports with the SEC as PRESIDENT & CEO of Black Diamond Therapeutics, Inc. (BDTX).
Signal8 holds 2 ownership filings by Velleca Mark A., all Form 4s, filed between Jan 31, 2025 and Jan 23, 2026. Those filings report 2 transactions, from Jan 30, 2025 to Jan 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Velleca Mark A.'s filings is in CAMBRIDGE, MA.
Recent filings by Velleca Mark A.
Other insiders filing for Black Diamond Therapeutics, Inc. (BDTX)
- Behbahani Ali, Director
- Raman Prakash, Director
- Kulkarni Samarth, Director
- Menzel Garry E, Director
- Dhingra Kapil, Director
- Campbell Shannon, Director